吉非替尼靶向治疗非小细胞肺癌的研究

吉非替尼是一种具有抗肿瘤活性的喹唑啉类衍生物,通过竞争抑制ATP与受体区结合,从而抑制酪氨酸激酶活化.吉非替尼主要应用于晚期非小细胞肺癌的二线和三线治疗,其抗肿瘤作用已得到许多研究者的认同.阐述了吉非替尼的药理学、临床研究,吉非替尼疗效的分子预测因素及不良反应的研究成果.

On the Gefitinib for the Targeted Therapy of Non-small-cell Lung Cancer

Gefitinib is a kind of Quinazoline with antineoplastic activity,this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR,thereby inhibiting receptor activation.Gefitinib as third line and second-line treatment for advanced non-small-cell lung cancer is identified by researchers.Pharmacology,clinical studies,the factor of molecule prediction and adverse reaction about Gefitinib are discussed.